Evaluation of low dose prostaglandin E1 treatment for ductus dependent congenital heart disease
- Cite this article as:
- Kramer, HH., Sommer, M., Rammos, S. et al. Eur J Pediatr (1995) 154: 700. doi:10.1007/BF02276712
- 123 Downloads
This study reports our experience with low-dose prostaglandin E1 (PGE1) treatment of 91 newborns with ductus dependent congenital heart disease (CHD). PGE1 efficacy, side-effects as well as the cardiovascular and respiratory profile of the patients were analysed. PGE1 doses > 0.02 μg/kg per minute were used for only 5.3% of the total 23 656 h of treatment. The mean systolic blood pressures did not differ from the normal mean for patients with cyanotic CHD, while the diastolic values were lowered. Respiratory support was required only during 13.7% of the total treatment time. Apnoeas occurred in 21 (38%) of the 55 spontaneously breathing infants, who all had a cyanotic CHD. The incidence of apnoeas was lower during treatment with doses < 0.01 μg/kg per minute.
Key wordsCongenital heart disease Prostaglandin E1 Efficacy Side-effects Cardiovascular and respiratory profile
balloon atrial septostomy
congenital heart disease